Skip to main content

AS/Spondyloarthritis

      RT @RichardPAConway: Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IM
      2 years 5 months ago
      Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk @RheumNow #EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N
      RT @RichardPAConway: Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month
      2 years 5 months ago
      Michielsens et al T2T tapering of TNFi in AxSpA and PsA. 72% tapered, 28% discontinued TNFi. Month 12 LDA 69% vs 73%.Month 12 dose 53% vs 91%. Flares 85% vs 78%. Needed more NSAID 54% vs 24% and steroid 30% vs 17%. @RheumNow #EULAR2022 OP0261 https://t.co/EDBPOgg4sX https://t.co/ckPqaTdm4B
      RT @doctorRBC: Increased risk of aortic regurgitation and atrial fibrillation in radiographic axSpA pts when compared to
      2 years 5 months ago
      Increased risk of aortic regurgitation and atrial fibrillation in radiographic axSpA pts when compared to general population. No significant risk for AV block (II-III). Unclear if treatment affects cardiac risk in these patients. @RheumNow #EULAR2022 ABST#POST0146
      RT @doctorRBC: COVID-19 mostly mild for majority of SpA patients.
      Steroid use associated with more severe COVID-19 outc
      2 years 5 months ago
      COVID-19 mostly mild for majority of SpA patients. Steroid use associated with more severe COVID-19 outcomes (OR 3.15). TNFi found to be protective! (OR 0.26) @RheumNow #EULAR2022 ABST#OP0254
      RT @RichardPAConway: Perrot et al. Factors assoc severe COVID in SpA. corticosteroid intake (3.15 [1.46-6.76]), age (OR=
      2 years 5 months ago
      Perrot et al. Factors assoc severe COVID in SpA. corticosteroid intake (3.15 [1.46-6.76]), age (OR=1.06 [1.04-1.08]) while anti-TNF (OR=0.26 [0.09-0.78]) was protective @RheumNow #EULAR2022 OP0254 https://t.co/bIiEW6efQ2
      RT @Yuz6Yusof: #OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and A
      2 years 5 months ago
      #OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH
      RT @doctorRBC: Ok to taper?
      In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o taper
      2 years 5 months ago
      Ok to taper? In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o tapering. 69% of tapered group remained in LDA, 73% no-taper group in LDA after 12 months. Taper group did use more NSAIDs, cDMARDs, steroids @RheumNow #EULAR2022 ABST#OP0261
      RT @doctorRBC: Pregnancy data in SpA from 122 pts
      40% flared during pregnancy, more frequent 2nd trimester, pts w/ axial
      2 years 5 months ago
      Pregnancy data in SpA from 122 pts 40% flared during pregnancy, more frequent 2nd trimester, pts w/ axial dz 7 pts required start of TNFi during 2nd or 3rd trimester 40% post-partum @RheumNow #EULAR2022 ABST#POST0151 https://t.co/cdFRhRuCVH
      RT @uptoTate: SpA pregnancies in #EULAR2022 POS1051 found that 40% of pts flared, particularly during their 2nd trimeste
      2 years 5 months ago
      SpA pregnancies in #EULAR2022 POS1051 found that 40% of pts flared, particularly during their 2nd trimester in those with axial involvement OR post-partum. Seven flares led to TNFi initiation in 2nd or 3rd trimesters and were without correlation in post-partum flares. @RheumNow https://t.co/0ZWjYMwmzn